🇺🇸 FDA
Pipeline program

VS-6766, VS-6063

VS-6766-201

Phase 2 small_molecule active

Quick answer

VS-6766, VS-6063 for Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) is a Phase 2 program (small_molecule) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Vera Therapeutics
Indication
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials